Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

An immune-protein signature combining TRAIL, IP-10 and CRP for accurate prediction of severe COVID-19 outcome

Niv Samuel Mastboim, Alon Angel, Oded Shaham, Tahel Ilan Ber, Roy Navon, Einav Simon, Michal Rosenberg, Yael Israeli, Mary Hainrichson, Noa Avni, Eran Reiner, Paul Feigin, Kfir Oved, Boaz Tadmor, Pierre Singer, Ilya Kagan, Shaul Lev, Dror Diker, Amir Jarjou’i, Ramzi Kurd, Eli Ben-Chetrit, Guy Danziger, Cihan Papan, Sergey Motov, Ma’anit Shapira, Michal Stein, Adi Klein, Tanya M Gottlieb, Eran Eden
doi: https://doi.org/10.1101/2021.06.27.21259196
Niv Samuel Mastboim
1MeMed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alon Angel
1MeMed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oded Shaham
1MeMed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tahel Ilan Ber
1MeMed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roy Navon
1MeMed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Einav Simon
1MeMed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michal Rosenberg
1MeMed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yael Israeli
1MeMed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Hainrichson
1MeMed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noa Avni
1MeMed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eran Reiner
1MeMed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Feigin
2Technion-Israel Institute of Technology, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kfir Oved
1MeMed, Israel
3Canopy Immuno-therapeutics, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boaz Tadmor
4Rabin Medical Center, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Singer
4Rabin Medical Center, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilya Kagan
4Rabin Medical Center, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaul Lev
4Rabin Medical Center, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dror Diker
4Rabin Medical Center, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amir Jarjou’i
5Shaare Zedek Medical Center, Hebrew University School of Medicine, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramzi Kurd
5Shaare Zedek Medical Center, Hebrew University School of Medicine, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eli Ben-Chetrit
5Shaare Zedek Medical Center, Hebrew University School of Medicine, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guy Danziger
6Saarland University Hospital, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cihan Papan
6Saarland University Hospital, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergey Motov
7Maimonides Medical Center, US
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ma’anit Shapira
8Hillel Yaffe Medical Center, Israel
2Technion-Israel Institute of Technology, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michal Stein
8Hillel Yaffe Medical Center, Israel
2Technion-Israel Institute of Technology, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adi Klein
8Hillel Yaffe Medical Center, Israel
2Technion-Israel Institute of Technology, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanya M Gottlieb
1MeMed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tanya.gottlieb{at}me-med.com
Eran Eden
1MeMed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tanya.gottlieb{at}me-med.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

BACKGROUND Accurately identifying COVID-19 patients at-risk to deteriorate remains challenging. Tools integrating host-protein expression have proven useful in determining infection etiology and hold potential for prognosticating disease severity.

METHODS Adults with COVID-19 were recruited at medical centers in Israel, Germany, and the United States. Severe outcome was defined as intensive care unit admission, non-invasive or invasive ventilation, or death. Tumor necrosis factor related apoptosis inducing ligand (TRAIL) and interferon gamma inducible protein-10 (IP-10; also known as CXCL10) and C-reactive protein (CRP) were measured using an analyzer providing values within 15 minutes. A signature indicating the likelihood of severe outcome was derived generating a score (0-100). Patients were assigned to 4 score bins.

RESULTS Between March and November 2020, 518 COVID-19 patients were enrolled, of whom 394 were eligible, 29% meeting a severe outcome. The signature’s area under the receiver operating characteristic curve (AUC) was 0.86 (95% confidence interval: 0.81-0.91). Performance was not confounded by age, sex, or comorbidities and superior to IL-6 (AUC 0.77; p = 0.033) and CRP (AUC 0.78; p < 0.001). Likelihood of severe outcome increased significantly (p < 0.001) with higher scores. The signature differentiated patients who further deteriorated after meeting a severe outcome from those who improved (p = 0.004) and projected 14-day survival probabilities (p < 0.001).

CONCLUSION The derived immune-protein signature combined with a rapid measurement platform is an accurate predictive tool for early detection of COVID-19 patients at-risk for severe outcome, facilitating timely care escalation and de-escalation and appropriate resource allocation.

FUNDING MeMed funded the study

Competing Interest Statement

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf. AK, BT, GD, DD, MSt, MSa, PS declare they have: received no support from any organization for the submitted work; have no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. AA, EE, ER, ES, KO, MH, MR, NA, NSM, OS, RN, TIB, TMG, and YKI declare they are employees of MeMed, hold stock and/or options and receive salaries. PF declares he holds MeMed stock options. SL declares to have received lecturing fees from MeMed. EE, ES, KO, MH, NSM, OS, RN, SL, TIB, TMG declare they are authors of pending or issued patent applications relating to the submitted work. AJ, EBS, IK, KR, SM, IK declare that their medical center received funding from MeMed for the described clinical study. CP declares to have received a research grant from MeMed.

Funding Statement

MeMed funded the clinical study described in the manuscript. MeMed provided the measurement platforms and consumables.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Maimonides Medical Center, New York, US, IRB#: 2020-05-21 Saarland University Medical Center, Homburg, Germany, IRB#: 1009-20 Hillel Yaffe Medical Center, Hadera, Israel, IRB#: 0059-15 Shaare Zedek Medical Center, Jerusalem, Israel, IRB#: 0313-20 Beilinson Medical Center, Petah Tikva, Israel, IRB#: 0257-20 Hasharon Medical Center, Petah Tikva, Israel, IRB#: 0257-20

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 02, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
An immune-protein signature combining TRAIL, IP-10 and CRP for accurate prediction of severe COVID-19 outcome
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
An immune-protein signature combining TRAIL, IP-10 and CRP for accurate prediction of severe COVID-19 outcome
Niv Samuel Mastboim, Alon Angel, Oded Shaham, Tahel Ilan Ber, Roy Navon, Einav Simon, Michal Rosenberg, Yael Israeli, Mary Hainrichson, Noa Avni, Eran Reiner, Paul Feigin, Kfir Oved, Boaz Tadmor, Pierre Singer, Ilya Kagan, Shaul Lev, Dror Diker, Amir Jarjou’i, Ramzi Kurd, Eli Ben-Chetrit, Guy Danziger, Cihan Papan, Sergey Motov, Ma’anit Shapira, Michal Stein, Adi Klein, Tanya M Gottlieb, Eran Eden
medRxiv 2021.06.27.21259196; doi: https://doi.org/10.1101/2021.06.27.21259196
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
An immune-protein signature combining TRAIL, IP-10 and CRP for accurate prediction of severe COVID-19 outcome
Niv Samuel Mastboim, Alon Angel, Oded Shaham, Tahel Ilan Ber, Roy Navon, Einav Simon, Michal Rosenberg, Yael Israeli, Mary Hainrichson, Noa Avni, Eran Reiner, Paul Feigin, Kfir Oved, Boaz Tadmor, Pierre Singer, Ilya Kagan, Shaul Lev, Dror Diker, Amir Jarjou’i, Ramzi Kurd, Eli Ben-Chetrit, Guy Danziger, Cihan Papan, Sergey Motov, Ma’anit Shapira, Michal Stein, Adi Klein, Tanya M Gottlieb, Eran Eden
medRxiv 2021.06.27.21259196; doi: https://doi.org/10.1101/2021.06.27.21259196

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Emergency Medicine
Subject Areas
All Articles
  • Addiction Medicine (433)
  • Allergy and Immunology (758)
  • Anesthesia (222)
  • Cardiovascular Medicine (3307)
  • Dentistry and Oral Medicine (365)
  • Dermatology (282)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1174)
  • Epidemiology (13391)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5167)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3281)
  • Health Policy (1144)
  • Health Systems and Quality Improvement (1196)
  • Hematology (432)
  • HIV/AIDS (1021)
  • Infectious Diseases (except HIV/AIDS) (14647)
  • Intensive Care and Critical Care Medicine (914)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (525)
  • Neurology (4941)
  • Nursing (262)
  • Nutrition (733)
  • Obstetrics and Gynecology (887)
  • Occupational and Environmental Health (796)
  • Oncology (2526)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (546)
  • Pediatrics (1303)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4221)
  • Public and Global Health (7522)
  • Radiology and Imaging (1710)
  • Rehabilitation Medicine and Physical Therapy (1016)
  • Respiratory Medicine (981)
  • Rheumatology (480)
  • Sexual and Reproductive Health (499)
  • Sports Medicine (425)
  • Surgery (550)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (206)